Chemomab Therapeutics (CMMB) EBITDA (2019 - 2023)
Chemomab Therapeutics (CMMB) EBITDA from Mar 31, 2019 to Mar 31, 2023. The TTM Chemomab Therapeutics (CMMB) EBITDA is -$32M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Chemomab Therapeutics (CMMB) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +100.44% |
| 3 Years TTM | +19.43% |
| All Time TTM | +19.44% |
Annual EBITDA change of Chemomab Therapeutics (CMMB)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$112M | +8.72% |
| 2024 | -$103M | +326.29% |
| 2023 | -$24M | -14.12% |
| 2022 | -$28M | +126.05% |
| 2021 | -$12M | +109.78% |
| 2020 | -$5.93M | -77.91% |
| 2019 | -$27M | +99.85% |
| 2018 | -$13M | -235.79% |
| 2017 | $9.89M | +109.98% |
| 2016 | $4.71M | N/A |